acalabrutinib acalabrutinib/acalabrutinib usage and dosage

Acalabrutinib/Acalabrutinib (Acalabrutinib) is available in the form of oral capsules after it is launched on the market. Patients are advised to swallow the entire capsule with water; patients are advised not to open, break or chew the capsule; Acalabrutinib can be taken with or without food. If a dose is missed by more than 3 hours, the dose should be skipped and the next dose should be taken at the regularly scheduled time. Additional acotinib capsules should not be taken to make up for a missed dose.

As monotherapy, the recommended dose of acotinib for patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL) is 100 mg orally every 12 hours until disease progression or unacceptable toxicity. As a combination therapy, acotinib can be used in combination with obinutuzumab. For patients with previously untreated CLL or SLL, 100 mg is recommended orally every 12 hours until disease progression or unacceptable toxicity occurs. Calculation starts at period 1 (each period is 28 days). Start using otuzumab in Cycle 2 for a total of 6 cycles and refer to its prescribing information for recommended dosage. If both drugs are administered on the same day, acotinib should be given before otuzumab.

Depending on the side effects the patient experiences, the doctor may temporarily or permanently stop treatment or reduce the dose of acotinib. Do not stop taking acotinib without consulting your doctor. Acotinib is not suitable for patients with severe liver damage; when used in combination with other drugs, it should be used under the guidance of a doctor.